Minerva Neurosciences Inc. (NASDAQ:NERV)’s traded shares stood at 0.32 million during the last session, with the company’s beta value hitting 0.88. At the close of trading, the stock’s price was $1.12, to imply a decrease of -5.08% or -$0.06 in intraday trading. The NERV share’s 52-week high remains $4.11, putting it -266.96% down since that peak but still an impressive -0.89% since price per share fell to its 52-week low of $1.13. The company has a valuation of $49.34M, with an average of 0.49 million shares in intraday trading volume over the past 10 days and average of 590.85K shares over the past 3 months.
Analysts have given a consensus recommendation of an Overweight for Minerva Neurosciences Inc. (NERV), translating to a mean rating of 2.20. Of 4 analyst(s) looking at the stock, 0 analyst(s) give NERV a Sell rating. 0 of those analysts rate the stock as Overweight while 1 advise Hold as 3 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -$0.22.
3 Tiny Stocks Primed to Explode The world’s greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We’ve set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
After registering a -5.08% downside in the last session, Minerva Neurosciences Inc. (NERV) has traded red over the past five days. The stock hit a weekly high of 1.3600 this Friday, 11/19/21, dropping -5.08% in its intraday price action. The 5-day price performance for the stock is -14.50%, and -13.85% over 30 days. With these gigs, the year-to-date price performance is -52.14%. Short interest in Minerva Neurosciences Inc. (NASDAQ:NERV) saw shorts transact 3.35 million shares and set a 0.92 days time to cover.
Analysts on Wall Street suggest a consensus price target of $8.33, implying an increase of 86.55% to the stock’s current value. The extremes give us $6.00 and $10.00 for target low and target high price respectively. As such, NERV has been trading -792.86% off suggested target high and -435.71% from its likely low.
Minerva Neurosciences Inc. (NERV) estimates and forecasts
Revenue is forecast to shrink -15.80% this quarter before falling -27.80% for the next one. The rating firms project that company’s revenue will shrink -98.40% compared to the previous financial year.
Revenue forecast for the current quarter as set by 3 analysts is $330k. Meanwhile, for the quarter ending Dec 2021, a total of 3 analyst(s) estimate revenue growth to $330k.
Minerva Neurosciences Inc. has its next earnings report out between August 02 and August 06. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too. Minerva Neurosciences Inc. has a forward dividend ratio of 0, with the share yield ticking at 0.00% to continue the rising pattern observed over the past year. The company’s average dividend yield trailing the past 5-year period is 0.00%.
Minerva Neurosciences Inc. (NASDAQ:NERV)’s Major holders
Minerva Neurosciences Inc. insiders hold 3.53% of total outstanding shares, with institutional holders owning 74.19% of the shares at 76.91% float percentage. In total, 74.19% institutions holds shares in the company, led by Federated Hermes, Inc. As of Mar 30, 2021, the company held over 9.61 million shares (or 22.49% of shares), all amounting to roughly $28.06 million.
The next major institution holding the largest number of shares is Vanguard Group, Inc. (The) with 4.42 million shares, or about 10.35% of shares outstanding. As of the market price on Mar 30, 2021, these shares were worth $12.91 million.
We also have Federated Hermes Kaufmann Fund and Federated Hermes Kaufmann Small Cap Fund as the top two Mutual Funds with the largest holdings of the Minerva Neurosciences Inc. (NERV) shares. Going by data provided on Jan 30, 2021, Federated Hermes Kaufmann Fund holds roughly 5.2 million shares. This is just over 12.17% of the total shares, with a market valuation of $16.59 million. Data from the same date shows that the other fund manager holds a little less at 4.27 million, or 10.00% of the shares, all valued at about 13.63 million.